[go: up one dir, main page]

NO991078D0 - HIV peptider, antigener, vaksine sammensetninger, immunoassay kit og en metode for Õ pÕvise antistoffer indusert av HIV - Google Patents

HIV peptider, antigener, vaksine sammensetninger, immunoassay kit og en metode for Õ pÕvise antistoffer indusert av HIV

Info

Publication number
NO991078D0
NO991078D0 NO991078A NO991078A NO991078D0 NO 991078 D0 NO991078 D0 NO 991078D0 NO 991078 A NO991078 A NO 991078A NO 991078 A NO991078 A NO 991078A NO 991078 D0 NO991078 D0 NO 991078D0
Authority
NO
Norway
Prior art keywords
hiv
antigens
peptides
vaccine compositions
antibodies induced
Prior art date
Application number
NO991078A
Other languages
English (en)
Other versions
NO991078L (no
NO311807B1 (no
Inventor
Birger Soerensen
Original Assignee
Bionor Immuno As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionor Immuno As filed Critical Bionor Immuno As
Priority to NO19991078A priority Critical patent/NO311807B1/no
Publication of NO991078D0 publication Critical patent/NO991078D0/no
Priority to CNA2008100921326A priority patent/CN101328210A/zh
Priority to CNA2008100921311A priority patent/CN101328209A/zh
Priority to DK00911492T priority patent/DK1159298T3/da
Priority to NZ525751A priority patent/NZ525751A/en
Priority to CNB008057354A priority patent/CN100387617C/zh
Priority to ES00911492T priority patent/ES2307496T4/es
Priority to NZ525752A priority patent/NZ525752A/en
Priority to SK1240-2001A priority patent/SK287382B6/sk
Priority to AU33358/00A priority patent/AU771827B2/en
Priority to AT00911492T priority patent/ATE397014T1/de
Priority to CZ20013195A priority patent/CZ300505B6/cs
Priority to PT00911492T priority patent/PT1159298E/pt
Priority to PCT/NO2000/000075 priority patent/WO2000052040A1/en
Priority to HU0200265A priority patent/HU229282B1/hu
Priority to NZ525753A priority patent/NZ525753A/en
Priority to IDW00200102137A priority patent/ID30497A/id
Priority to NZ514619A priority patent/NZ514619A/en
Priority to JP2000602264A priority patent/JP2002541069A/ja
Priority to EP00911492A priority patent/EP1159298B1/en
Priority to DE60039036T priority patent/DE60039036D1/de
Priority to BR0008741-6A priority patent/BR0008741A/pt
Priority to CA002363947A priority patent/CA2363947C/en
Priority to EA200100943A priority patent/EA004802B9/ru
Priority to US09/674,674 priority patent/US6706859B1/en
Priority to CNA2008100921330A priority patent/CN101328208A/zh
Publication of NO991078L publication Critical patent/NO991078L/no
Priority to ZA200107072A priority patent/ZA200107072B/xx
Publication of NO311807B1 publication Critical patent/NO311807B1/no
Priority to HK02106292.0A priority patent/HK1044778B/zh
Priority to US10/659,324 priority patent/US7311915B2/en
Priority to US11/865,109 priority patent/US7709004B2/en
Priority to US11/865,106 priority patent/US7709003B2/en
Priority to CY20081100922T priority patent/CY1108299T1/el
Priority to JP2010275025A priority patent/JP5313998B2/ja
Priority to JP2012239940A priority patent/JP5695010B2/ja
Priority to JP2012240131A priority patent/JP5695012B2/ja
Priority to JP2013249096A priority patent/JP5814331B2/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
NO19991078A 1999-03-04 1999-03-04 HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV NO311807B1 (no)

Priority Applications (36)

Application Number Priority Date Filing Date Title
NO19991078A NO311807B1 (no) 1999-03-04 1999-03-04 HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
CNA2008100921330A CN101328208A (zh) 1999-03-04 2000-03-02 Hiv肽，抗原，疫苗组合物，检测hiv所诱导的抗体的免疫测定试剂盒及方法
JP2000602264A JP2002541069A (ja) 1999-03-04 2000-03-02 Ｈｉｖペプチド、抗原、ワクチン組成物、免疫学的検定キット及びｈｉｖによって誘発された抗体を検出する方法
EP00911492A EP1159298B1 (en) 1999-03-04 2000-03-02 Hiv peptides, antigens and vaccine compositions
DK00911492T DK1159298T3 (da) 1999-03-04 2000-03-02 HIV-peptider, antigener og vaccinekompositioner
NZ525751A NZ525751A (en) 1999-03-04 2000-03-02 HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
CNB008057354A CN100387617C (zh) 1999-03-04 2000-03-02 Hiv肽,抗原,疫苗组合物,检测hiv所诱导的抗体的免疫测定试剂盒及方法
BR0008741-6A BR0008741A (pt) 1999-03-04 2000-03-02 Peptìdeo de hiv, antìgenos, composições de vacina, kit de imunoensaio e método de detecção de anticorpos induzidos por hiv
NZ525752A NZ525752A (en) 1999-03-04 2000-03-02 HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
SK1240-2001A SK287382B6 (sk) 1999-03-04 2000-03-02 Očkovacia kompozícia
AU33358/00A AU771827B2 (en) 1999-03-04 2000-03-02 HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
AT00911492T ATE397014T1 (de) 1999-03-04 2000-03-02 Hiv-peptide, antigene und impfstoffzusammensetzungen
CZ20013195A CZ300505B6 (cs) 1999-03-04 2000-03-02 Vakcinacní prípravek
PT00911492T PT1159298E (pt) 1999-03-04 2000-03-02 Péptidos de hiv, antigénios, composições de vacinas, kit de imunoensaio e um método de detecção de anticorpos induzidos por hiv
PCT/NO2000/000075 WO2000052040A1 (en) 1999-03-04 2000-03-02 Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv
HU0200265A HU229282B1 (en) 1999-03-04 2000-03-02 Hiv vaccine compositions
NZ525753A NZ525753A (en) 1999-03-04 2000-03-02 HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
IDW00200102137A ID30497A (id) 1999-03-04 2000-03-02 Peptida hiv, antigen, komposisi vaksin, kit imunoasai dan metoda untuk mendeteksi antibodi yang diinduksi oleh hiv
NZ514619A NZ514619A (en) 1999-03-04 2000-03-02 HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
CNA2008100921326A CN101328210A (zh) 1999-03-04 2000-03-02 Hiv肽，抗原，疫苗组合物，检测hiv所诱导的抗体的免疫测定试剂盒及方法
DE60039036T DE60039036D1 (de) 1999-03-04 2000-03-02 Hiv-peptide, antigene und impfstoffzusammensetzungen
CNA2008100921311A CN101328209A (zh) 1999-03-04 2000-03-02 Hiv肽，抗原，疫苗组合物，检测hiv所诱导的抗体的免疫测定试剂盒及方法
ES00911492T ES2307496T4 (es) 1999-03-04 2000-03-02 Composiciones de vacuna, antígenos y péptidos de VIH
CA002363947A CA2363947C (en) 1999-03-04 2000-03-02 Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv
EA200100943A EA004802B9 (ru) 1999-03-04 2000-03-02 МОДИФИЦИРОВАННЫЕ ВИЧ-ПЕПТИДЫ НА ОСНОВЕ БЕЛКА gag p24, АНТИГЕНЫ, ВАКЦИННЫЕ КОМПОЗИЦИИ, НАБОР ДЛЯ ИММУНОАНАЛИЗА И СПОСОБ ОПРЕДЕЛЕНИЯ ВИЧ-ИНДУЦИРОВАННЫХ АНТИТЕЛ
US09/674,674 US6706859B1 (en) 1999-03-04 2000-03-02 HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
ZA200107072A ZA200107072B (en) 1999-03-04 2001-08-27 HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV.
HK02106292.0A HK1044778B (zh) 1999-03-04 2002-08-27 Hiv肽，抗原，疫苗組合物，檢測hiv所誘導的抗體的免疫測定試劑盒及方法
US10/659,324 US7311915B2 (en) 1999-03-04 2003-09-11 Method of producing an HIV-1 immune response
US11/865,109 US7709004B2 (en) 1999-03-04 2007-10-01 Method of producing an HIV-1 immune response
US11/865,106 US7709003B2 (en) 1999-03-04 2007-10-01 Method of producing an HIV-1 immune response
CY20081100922T CY1108299T1 (el) 1999-03-04 2008-08-28 Πεπτιδια του ιου ανθρωπινης ανοσοανεπαρκειας (hiv), αντιγονα και συνθεσεις εμβολιου
JP2010275025A JP5313998B2 (ja) 1999-03-04 2010-12-09 Ｈｉｖペプチド、抗原、ワクチン組成物、免疫学的検定キット及びｈｉｖによって誘発された抗体を検出する方法
JP2012239940A JP5695010B2 (ja) 1999-03-04 2012-10-31 Ｈｉｖペプチド、抗原、ワクチン組成物、免疫学的検定キット及びｈｉｖによって誘発された抗体を検出する方法
JP2012240131A JP5695012B2 (ja) 1999-03-04 2012-10-31 Ｈｉｖペプチド、抗原、ワクチン組成物、免疫学的検定キット及びｈｉｖによって誘発された抗体を検出する方法
JP2013249096A JP5814331B2 (ja) 1999-03-04 2013-12-02 Ｈｉｖペプチド、抗原、ワクチン組成物、免疫学的検定キット及びｈｉｖによって誘発された抗体を検出する方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO19991078A NO311807B1 (no) 1999-03-04 1999-03-04 HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV

Publications (3)

Publication Number Publication Date
NO991078D0 true NO991078D0 (no) 1999-03-04
NO991078L NO991078L (no) 2000-09-05
NO311807B1 NO311807B1 (no) 2002-01-28

Family

ID=19903050

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19991078A NO311807B1 (no) 1999-03-04 1999-03-04 HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV

Country Status (23)

Country Link
US (4) US6706859B1 (no)
EP (1) EP1159298B1 (no)
JP (5) JP2002541069A (no)
CN (4) CN101328208A (no)
AT (1) ATE397014T1 (no)
AU (1) AU771827B2 (no)
BR (1) BR0008741A (no)
CA (1) CA2363947C (no)
CY (1) CY1108299T1 (no)
CZ (1) CZ300505B6 (no)
DE (1) DE60039036D1 (no)
DK (1) DK1159298T3 (no)
EA (1) EA004802B9 (no)
ES (1) ES2307496T4 (no)
HK (1) HK1044778B (no)
HU (1) HU229282B1 (no)
ID (1) ID30497A (no)
NO (1) NO311807B1 (no)
NZ (4) NZ514619A (no)
PT (1) PT1159298E (no)
SK (1) SK287382B6 (no)
WO (1) WO2000052040A1 (no)
ZA (1) ZA200107072B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020075789A (ko) 2000-02-04 2002-10-05 듀크 유니버시티 인체 면역결핍 바이러스 백신
NO314588B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
NO314587B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
EP2392587B1 (en) 2006-03-10 2016-05-04 Peptcell Limited Peptide sequences and compositions
BRPI0914224A2 (pt) 2008-06-19 2019-09-24 Variation Biotechnologies Inc composições e métodos para tratar a gripe
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
JP5854559B2 (ja) 2009-07-06 2016-02-09 ヴァリエーション バイオテクノロジーズ インコーポレイテッド 小胞を調製する方法及びこれから製造される製剤
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
BR112013000394B8 (pt) 2010-07-06 2022-01-18 Variation Biotechnologies Inc Composição imunogênica, uso da mesma e método para preparar a referida composição
AU2011335551B2 (en) * 2010-12-02 2016-10-06 Bionor Immuno As Peptide scaffold design
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US20140356399A1 (en) 2012-01-12 2014-12-04 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
EP4008354A1 (en) 2012-01-27 2022-06-08 Variation Biotechnologies Inc. Methods and compositions for therapeutic agents
WO2013182661A1 (en) * 2012-06-06 2013-12-12 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
EP2858665A1 (en) 2012-06-06 2015-04-15 Bionor Immuno AS Vaccine
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
WO2015022401A1 (en) * 2013-08-14 2015-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Immunoadjuvant compositions and uses thereof
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
WO2015086738A2 (en) * 2013-12-11 2015-06-18 Bionor Immuno As Hiv vaccine
WO2015110659A1 (en) * 2014-01-27 2015-07-30 Bionor Immuno As Methods of immunization with a vaccine inducing a humoral immune response and with a vaccine inducing a cellular immune response
CA2936335A1 (en) 2014-01-27 2015-07-30 Bionor Immuno As Dosage regimen for hiv vaccine
US10143737B2 (en) 2014-01-27 2018-12-04 Bionor Pharma Asa Method for the vaccination against HIV
MA52906A (fr) * 2014-04-03 2021-04-21 Amgen Inc Procédé de préparation d'amg 416
US20170165321A1 (en) 2014-07-11 2017-06-15 Bionor Immuno As Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids)
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US20180140694A1 (en) 2015-05-04 2018-05-24 Bionor Immuno As Dosage regimen for hiv vaccine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6713287A (en) 1986-01-06 1987-07-09 F. Hoffmann-La Roche & Co. Expression of htlv-iii gag-gene
US4925784A (en) 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
GB8629116D0 (en) 1986-12-05 1987-01-14 Hoffmann La Roche Env/gag polypeptides
IE63455B1 (en) 1987-09-04 1995-04-19 Int Murex Tech Corp Immunoassay and biological constructs for use therein
US4888290A (en) * 1987-11-06 1989-12-19 Coulter Corporation Monoclonal antibody specific to HIV antigens
EP0356007A3 (en) * 1988-07-22 1991-07-03 Medical Research Council Antigenic determinants
KR940000755B1 (ko) * 1990-02-16 1994-01-29 유나이티드 바이오메디칼 인코오포레이티드 Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
SE468168B (sv) 1990-02-20 1992-11-16 Replico Medical Ab Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
FR2703252B1 (fr) * 1993-03-31 1996-09-06 Fernand Narbey Torossian Complexe immunomodulateur anti SIDA.
WO1994028871A1 (en) 1993-06-07 1994-12-22 Endocon, Inc. Implant stimulated cellular immunity
KR100235849B1 (ko) * 1993-10-19 1999-12-15 에가시라 구니오 HIV에 대한 면역응답을 유도할 수 있는 펩티드 및 그 펩티드를 함유하는 항 AIDS 예방, 치료제(Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS)
FR2731013B1 (fr) * 1995-02-27 1997-05-16 Inst Nat Sante Rech Med Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications
WO1998040744A1 (de) * 1997-03-10 1998-09-17 Roche Diagnostics Gmbh Verfahren zur simultanen bestimmung von hiv-antigenen und hiv-antikörpern

Also Published As

Publication number Publication date
CY1108299T1 (el) 2014-02-12
JP2013032384A (ja) 2013-02-14
HU229282B1 (en) 2013-10-28
CZ20013195A3 (cs) 2002-02-13
SK287382B6 (sk) 2010-08-09
NZ525752A (en) 2004-10-29
CN101328208A (zh) 2008-12-24
US20080107669A1 (en) 2008-05-08
US20040259797A1 (en) 2004-12-23
CZ300505B6 (cs) 2009-06-03
ZA200107072B (en) 2002-11-27
JP5313998B2 (ja) 2013-10-09
HK1044778B (zh) 2009-04-24
DE60039036D1 (de) 2008-07-10
AU771827B2 (en) 2004-04-01
JP5814331B2 (ja) 2015-11-17
CN101328209A (zh) 2008-12-24
US6706859B1 (en) 2004-03-16
SK12402001A3 (sk) 2002-02-05
US7709004B2 (en) 2010-05-04
NZ514619A (en) 2003-10-31
WO2000052040A1 (en) 2000-09-08
NZ525751A (en) 2004-10-29
CA2363947C (en) 2008-05-20
JP5695010B2 (ja) 2015-04-01
US20080107670A1 (en) 2008-05-08
JP5695012B2 (ja) 2015-04-01
CN101328210A (zh) 2008-12-24
JP2013032386A (ja) 2013-02-14
EP1159298A1 (en) 2001-12-05
NZ525753A (en) 2004-10-29
NO991078L (no) 2000-09-05
CA2363947A1 (en) 2000-09-08
ID30497A (id) 2001-12-13
HUP0200265A2 (en) 2002-06-29
EA004802B1 (ru) 2004-08-26
AU3335800A (en) 2000-09-21
BR0008741A (pt) 2002-01-08
CN1346367A (zh) 2002-04-24
HK1044778A1 (en) 2002-11-01
PT1159298E (pt) 2008-09-04
US7311915B2 (en) 2007-12-25
US7709003B2 (en) 2010-05-04
EA200100943A1 (ru) 2002-02-28
NO311807B1 (no) 2002-01-28
CN100387617C (zh) 2008-05-14
ES2307496T4 (es) 2015-03-06
JP2002541069A (ja) 2002-12-03
JP2011074081A (ja) 2011-04-14
ES2307496T3 (es) 2008-12-01
ATE397014T1 (de) 2008-06-15
DK1159298T3 (da) 2008-08-25
EA004802B9 (ru) 2015-03-31
JP2014043468A (ja) 2014-03-13
EP1159298B1 (en) 2008-05-28

Similar Documents

Publication Publication Date Title
NO991078L (no) HIV peptider, antigener, vaksine sammensetninger, immunoassay kit og en metode for Õ pÕvise antistoffer indusert av HIV
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
Henderson et al. Direct identification of class II histocompatibility DR proteins in preparations of human T-cell lymphotropic virus type III
BR0210598A (pt) Complexo solúvel que compreende uma glicoproteìna retroviral de superfìcie
AP2002002592A0 (en) Vaccine for the prophylactic or therapeutic immunization against HIV.
IE852587L (en) Antigens, immunogenic compositions and detection of¹antibodies
WO2002020555A3 (en) Hiv peptides from tat, rev and wef conserved regions and their application as e.g.vaccine components
Shafferman et al. Patterns of antibody recognition of selected conserved amino acid sequences from the HIV envelope in sera from different stages of HIV infection
EP1016671A3 (en) Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1)
Kennedy et al. Use of a resin-bound synthetic peptide for identifying a neutralizing antigenic determinant associated with the human immunodeficiency virus envelope.
EP1417222B1 (en) Isolated polypeptides based on the neutralizing epitope of the p17 protein of hiv useful as vaccines, and neutralizing anti-p17 antibodies which specifically recognize said neutralizing epitope
Im et al. Induction of long‐lasting multi‐specific CD8+ T cells by a four‐component DNA‐MVA/HIVA‐RENTA candidate HIV‐1 vaccine in rhesus macaques
DeVICO et al. Purification and partial characterization of human immunodeficiency virus type 2 reverse transcriptase
GR3033885T3 (en) Synthetic antigens for the detection of aids-related disease caused by LAV-2.
Pyle et al. Purification and characterization of the external envelope glycoprotein from two human immunodeficiency virus type 1 variants, HTLV-IIIB and HTLV-IIIRF
Partidos et al. The binding affinity of double‐stranded RNA motifs to HIV‐1 Tat protein affects transactivation and the neutralizing capacity of anti‐Tat antibodies elicited after intranasal immunization
Viscidi et al. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay
Okuda et al. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection
WIELAND et al. Antigenic domains of the HIV-1 vif protein as recognized by human sera and murine monoclonal antibodies
Chattopadhya et al. Profile of antigen-specific antibody response detectable by western blot in relation to diagnostic criteria for human immunodeficiency virus type-1 (HIV-1) infection
Chen et al. A common immunological epitope existing between HIV-1 gp41 and human interferon-α and-β
FR2874017B1 (fr) Peptides vih-1 modifies et leur utilisation en detection d'anticorps anti-vih
Krohn et al. Proliferative T‐Cell Response to HIV Envelope Glycoprotein in Immunized and Infected Primates and Human Beings
Gnann Jr et al. Designing Peptides to Immunologically Distinguish Specific Human Immunodeficiency Virus Isolates
MORIMOTO et al. Use of the recombinant chimera proteins, LacZ-Env and Gag-Env, for immunological studies on HIV-1 infection

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees